Indirect Comparisons of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with R/R MCL: An Extended Follow-up Analysis,ADVANCES IN THERAPY,2025 年 42 卷 6 期 (2937 - 2949)

Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study,AMERICAN JOURNAL OF HEMATOLOGY,2023 年 98 卷 11 期 (1742 - 1750)

Lijuan Deng, Keshu Zhou, Lihong Liu, et al. Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study. Blood Advances. 2023; 7(16): 4349-4357.,Blood Advances,7(16): 4349-4357.

Clinical Characteristics and Prognosis of Primary Central Nervous System Lymphoma: A Retrospective Analysis,CANCERS,2026 年 18 卷 3 期